Sign in
Taking people in ChinaNo phase

Measuring Iris Blood Flow With Eye Scans in Diabetic Neovascular Glaucoma

Compares iris blood flow by eye scan in adults with type 2 diabetes.

Key facts

Who runs it
Qilu Hospital of Shandong University
Where
Jinan, ChinaSee the site
Trial code
Registry title
Observation of Iris Blood Flow Via OCTA in Diabetic Neovascular Glaucoma
Status
Recruiting
People taking part
98 people, planned
Started
23 May 2026
Expected to end
31 Dec 2026
Type of study
Observational, 4 groups
Record updated
28 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who have type 2 diabetes, with or without eye complications, and healthy volunteers. Everyone has a painless iris eye scan (OCTA) that shows blood flow.

Age
18 years or older
Sex
Men and women can join.
Disease stage
Four groups: healthy people, type 2 diabetes without diabetic retinopathy, type 2 diabetes with diabetic retinopathy, and type 2 diabetes with diabetic retinopathy and neovascular glaucoma.
Earlier treatment
No eye surgery on the studied eye (including cataract, glaucoma or retina surgery). No laser or eye injection treatment on that eye in the past 6 months.

Main reasons for not taking part

  • Other eye diseases that could affect the results, such as uveitis or retinal vein occlusion
  • Type 1 diabetes, gestational diabetes or other specific types of diabetes
  • Autoimmune or blood diseases
  • A recent acute illness in the past 3 months, or severe liver or kidney problems
  • Cannot keep the head still for a good scan, or cannot understand or cooperate with the exam

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Aged ≥ 18 years of age, regardless of gender, with or without type 2 diabetes mellitus and its associated ocular complications; clear consciousness, capable of cooperating with iris OCTA examination (able to stabilize the head to guarantee successful acquisition and interpretable images)
  • Voluntary participation in this study with signed written informed consent
  • No history of intraocular surgery in the examined eye (including cataract surgery, glaucoma filtering surgery, retinal surgery, etc.)
  • General physical conditions: No acute disease episodes within the recent 3 months (such as acute myocardial infarction, stroke, diabetic ketoacidosis); no severe liver or renal dysfunction (ALT and AST ≤ 2 times the upper limit of normal, serum creatinine ≤ 133 μmol/L)

Who cannot take part

  • The studied eye suffers from other ocular diseases that may interfere with examination results apart from the disorders specified in Criterion 1 of the inclusion criteria (e.g., uveitis, retinal vein occlusion, high myopia-related fundus lesions, etc.); invasive ocular treatments were administered to the studied eye within the past 6 months (e.g., retinal laser photocoagulation, intravitreal injection, etc.)
  • Subjects complicated with type 1 diabetes mellitus, gestational diabetes mellitus or other specific types of diabetes mellitus; those with autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus) or hematological diseases (e.g., leukemia, aplastic anemia); individuals who have taken medications affecting ocular microcirculation (e.g., alprostadil, nitrates) within the past 3 months and are unable to discontinue such drugs
  • Subjects with severe head tremors and inability to maintain a fixed posture during examination, resulting in substandard OCTA image quality (interpretable area < 80%); those with mental disorders or cognitive dysfunction who fail to understand and cooperate with the examination procedures

Where in China

  • Qilu Hospital of Shandong UniversityJinan, ChinaContact: Yuting Zhang, Doctor of MedicineTaking people

About the trial

What the trial wants to find out

The goal of this observational study is to quantify iris blood flow via non-invasive eye scanning for evaluating ocular lesions in adults aged 18 years and older, including healthy volunteers, patients with type 2 diabetes mellitus (T2DM) without fundus lesions, T2DM patients with diabetic retinopathy (DR), and T2DM patients complicated with both DR and neovascular glaucoma (NVG). The main questions it aims to answer are:

Read full original descriptionShow less

* Does iris blood flow fraction at six pupillary quadrants differ significantly among people with different stages of type 2 diabetic eye complications? * Are there quadrant-specific and gender-based differences in iris microcirculation changes caused by diabetic eye diseases? If there is a comparison group: Researchers will compare iris blood flow data from four groups (healthy controls, T2DM without DR, T2DM with DR, T2DM with DR + NVG) to see how iris blood circulation changes as diabetic eye conditions get worse, and test whether iris blood flow indicators can help identify patients with neovascular glaucoma.

Participants will complete the following tasks:

* Provide basic personal information, past medical history and recent laboratory test results from their routine medical records; * Receive a painless, non-invasive iris OCTA eye scan to capture iris blood flow images at six quadrants around the pupil.

The 4 groups in the trial

  • Control

    Patients without type 2 diabetes

  • NDR

    Patients with type 2 diabetes but without diabetic retinopathy

  • DR

    Patients with type 2 diabetic retinopathy

  • DR+NVG

    Patients with type 2 diabetic retinopathy and neovascular glaucoma

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Analysis of the Identification Value and Quadrant Characteristics of Iris OCTA Blood Flow Quantification in Type 2 Diabetic Neovascular Glaucoma
Plain-language title
Measuring Iris Blood Flow With Eye Scans in Diabetic Neovascular GlaucomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
28 July 2026